GERD - Barrett - Adenocarcinoma: Do we have suitable prognostic and predictive molecular markers?

Gastroenterology Research and Practice

Volumn 2013, Issue , 2013, Pages

  Illig, Romana ^a   Klieser, Eckhard ^a   Kiesslich, Tobias ^a   Neureiter, Daniel ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CADHERIN; CATHEPSIN D; CYCLIN A; CYCLIN D1; DIPEPTIDYL PEPTIDASE IV; ENDOGLIN; EPHRIN B3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 27; INTESTINAL TREFOIL FACTOR; KI 67 ANTIGEN; MESSENGER RNA; MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 196A; MICRORNA 196B; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P16; SIRTUIN 2; SUCRASE ISOMALTASE; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

BARRETT ESOPHAGUS; CANCER PROGNOSIS; DISEASE COURSE; DISEASE MARKER; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; FLOW CYTOMETRY; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENE LOCUS; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876524563     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2013/643084     Document Type: Review

References (126)

1. Nebel O. T., Fornes M. F., Castell D. O., Symptomatic gastroesophageal reflux: incidence and precipitating factors. American Journal of Digestive Diseases 1976 21 11 953 956 2-s2.0-0017202313
2. Rubenstein J. H., Morgenstern H., Appelman H., Prediction of Barrett's esophagus among men. American Journal of Gastroenterology 2013
3. Reid B. J., Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology Clinics of North America 1991 20 4 817 834 2-s2.0-0026039730
4. Weinstein W. M., Ippoliti A. F., The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointestinal Endoscopy 1996 44 1 91 95 2-s2.0-0029736957 (Pubitemid 26268669)
5. Booth C. L., Thompson K. S., Barrett's esophagus: a review of diagnostic criteria, clinical surveillance practices and new developments. Journal of Gastrointestinal Oncology 2012 3 3 232 242
6. Souza R. F., Krishnan K., Spechler S. J., Acid, Bile, and CDX: the ABCs of making Barrett's metaplasia. American Journal of Physiology 2008 295 2 G211 G218 2-s2.0-52449108090 10.1152/ajpgi.90250.2008
7. Playford R. J., New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006 55 4 442 443 2-s2.0-33645131562 10.1136/gut.2005.083600
8. Jenkins G. J. S., Doak S. H., Parry J. M., D'Souza F. R., Griffiths A. P., Baxter J. N., Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. British Journal of Surgery 2002 89 7 824 837 2-s2.0-0036066913 10.1046/j.1365-2168.2002.02107.x (Pubitemid 34779566)
9. Koppert L. B., Wijnhoven B. P. L., Van Dekken H., Tilanus H. W., Dinjens W. N. M., The molecular biology of esophageal adenocarcinoma. Journal of Surgical Oncology 2005 92 3 169 190 2-s2.0-28844456547 10.1002/jso.20359 (Pubitemid 41779299)
10. Reid B. J., Li X., Galipeau P. C., Vaughan T. L., Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nature Reviews Cancer 2010 10 2 87 101 2-s2.0-75149134769 10.1038/nrc2773
11. Shaheen N. J., Crosby M. A., Bozymski E. M., Sandler R. S., Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000 119 2 333 338 2-s2.0-0033866197 (Pubitemid 30621983)
12. Sikkema M., de Jonge P. J. F., Steyerberg E. W., Kuipers E. J., Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2010 8 3 235 244 2-s2.0-77349099667 10.1016/j.cgh.2009.10.010
13. Haggitt R. C., Barrett's esophagus, dysplasia, and adenocarcinoma. Human Pathology 1994 25 10 982 993 2-s2.0-0027993158 10.1016/0046-8177(94)90057-4 (Pubitemid 24313642)
14. Spechler S. J., Sharma P., Souza R. F., Inadomi J. M., Shaheen N. J., American gastroenterological association technical review on the management of Barrett's esophagus. Gastroenterology 2011 140 3 e18 e52 2-s2.0-79952305740 10.1053/j.gastro.2011.01.031
15. Chaves P., Cardoso P., Mendes De Almeida J. C., Pereira A. D., Leitão C. N., Soares J., Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation. Human Pathology 1999 30 11 1291 1295 2-s2.0-0032719019 10.1016/S0046-8177(99) 90058-8 (Pubitemid 29534289)
16. Spechler S. J., Barrett's esophagus. Seminars in Oncology 1994 21 4 431 437 2-s2.0-0028146367 (Pubitemid 24256833)
17. Riddell R. H., Goldman H., Ransohoff D. F., Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Human Pathology 1983 14 11 931 966 2-s2.0-0021017589 (Pubitemid 14209714)
18. Goldblum J. R., Barrett's esophagus and Barrett's-related dysplasia. Modern Pathology 2003 16 4 316 324 2-s2.0-0037393206 10.1097/01.MP.0000062996. 66432.12 (Pubitemid 36443981)
19. Barr H., Upton M. P., Orlando R. C., Barrett's esophagus: histology and immunohistology. Annals of the New York Academy of Sciences 2011 1232 76 92
20. Baretton G. B., Aust D. E., Barrett's esophagus. An update. Pathologe 2012 33 1 5 16
21. Fléjou J. F., Svrcek M., Barrett's oesophagus-a pathologist's view. Histopathology 2007 50 1 3 14 2-s2.0-33845660390 10.1111/j.1365-2559.2006. 02569.x (Pubitemid 44953394)
22. Curvers W. L., Ten Kate F. J., Krishnadath K. K., Visser M., Elzer B., Baak L. C., Bohmer C., Mallant-Hent R. C., Van Oijen A., Naber A. H., Scholten P., Busch O. R., Blaauwgeers H. G. T., Meijer G. A., Bergman J. J. G. H. M., Low-grade dysplasia in barrett's esophagus: overdiagnosed and underestimated. American Journal of Gastroenterology 2010 105 7 1523 1530 2-s2.0-77954424898 10.1038/ajg.2010.171
23. Wani S., Puli S. R., Shaheen N. J., Westhoff B., Slehria S., Bansal A., Rastogi A., Sayana H., Sharma P., Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. American Journal of Gastroenterology 2009 104 2 502 513 2-s2.0-59749088947 10.1038/ajg.2008.31
24. Coupland V. H., Allum W., Blazeby J. M., Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer 2012 12, article 11
25. Schlansky B., Dimarino A. J. Jr., Loren D., A survey of oesophageal cancer: pathology, stage and clinical presentation. Alimentary Pharmacology & Therapeutics 2006 23 5 587 593
26. Gerson L. B., Shetler K., Triadafilopoulos G., Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002 123 2 461 467 2-s2.0-0036320158 10.1053/gast.2002.34748 (Pubitemid 34827190)
27. Rex D. K., Cummings O. W., Shaw M., Cumings M. D., Wong R. K. H., Vasudeva R. S., Dunne D., Rahmani E. Y., Helper D. J., Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003 125 6 1670 1677 2-s2.0-0344628832 10.1053/j.gastro.2003.09.030 (Pubitemid 37500431)
28. Ward E. M., Wolfsen H. C., Achem S. R., Loeb D. S., Krishna M., Hemminger L. L., DeVault K. R., Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. American Journal of Gastroenterology 2006 101 1 12 17 2-s2.0-33644860915 10.1111/j.1572-0241. 2006.00379.x (Pubitemid 43381703)
29. Reid B. J., Haggitt R. C., Rubin C. E., Roth G., Surawicz C. M., Van Belle G., Lewin K., Weinstein W. M., Antonioli D. A., Goldman H., MacDonald W., Owen D., Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Human Pathology 1988 19 2 166 178 2-s2.0-0023906902 (Pubitemid 18091022)
30. Montgomery E., Bronner M. P., Goldblum J. R., Greenson J. K., Haber M. M., Hart J., Lamps L. W., Lauwers G. Y., Lazenby A. J., Lewin D. N., Robert M. E., Toledano A. Y., Shyr Y., Washington K., Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Human Pathology 2001 32 4 368 378 2-s2.0-0035028767 10.1053/hupa.2001.23510 (Pubitemid 32378298)
31. Somerville M., Garside R., Pitt M., Stein K., Surveillance of Barrett's oesophagus: is it worthwhile? European Journal of Cancer 2008 44 4 588 599 2-s2.0-40449136001 10.1016/j.ejca.2008.01.015
32. Gutman S., Kessler L. G., The US Food and Drug Administration perspective on cancer biomarker development. Nature Reviews Cancer 2006 6 7 565 571 2-s2.0-33745560074 10.1038/nrc1911 (Pubitemid 43980545)
33. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics 2001 69 3 89 95
34. Brennan D. J., Kelly C., Rexhepaj E., Dervan P. A., Duffy M. J., Gallagher W. M., Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics and Proteomics 2007 4 3 121 134 2-s2.0-34249317273 (Pubitemid 46807339)
35. Pepe M. S., Etzioni R., Feng Z., Potter J. D., Thompson M. L., Thornquist M., Winget M., Yasui Y., Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 2001 93 14 1054 1061 2-s2.0-0035908491 (Pubitemid 32717537)
36. McShane L. M., Altman D. G., Sauerbrei W., Taube S. E., Gion M., Clark G. M., Reporting recommendations for tumour Marker prognostic studies (REMARK). British Journal of Cancer 2005 93 4 387 391 2-s2.0-24944452378 10.1038/sj.bjc.6602678 (Pubitemid 43080010)
37. Fitzgerald R. C., Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006 55 12 1810 1818 2-s2.0-33845380456 10.1136/gut.2005.089144 (Pubitemid 44893583)
38. Chen H., Fang Y., Tevebaugh W., Molecular mechanisms of Barrett's esophagus. Digestive Diseases and Sciences 2011 56 12 3405 3420
39. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
40. Clément G., Braunschweig R., Pasquier N., Bosman F. T., Benhattar J., Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. Journal of Pathology 2006 208 1 100 107 2-s2.0-29744452213 10.1002/path.1884 (Pubitemid 43025708)
41. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., Olaru A., Wang S., Mori Y., Deacu E., Hamilton J., Kan T., Krasna M. J., Beer D. G., Pepe M. S., Abraham J. M., Feng Z., Schmiegel W., Greenwald B. D., Meltzer S. J., Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005 24 25 4138 4148 2-s2.0-21244467485 10.1038/sj.onc.1208598 (Pubitemid 40897058)
42. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
43. Feber A., Xi L., Pennathur A., Gooding W. E., Bandla S., Wu M., Luketich J. D., Godfrey T. E., Litle V. R., MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Annals of Thoracic Surgery 2011 91 5 1523 1530 2-s2.0-79955375953 10.1016/j.athoracsur.2011.01.056
44. Hu Y., Correa A. M., Hoque A., Guan B., Ye F., Huang J., Swisher S. G., Wu T. T., Ajani J. A., Xu X. C., Prognostic significance of differentially expressed miRNAs in esophageal cancer. International Journal of Cancer 2011 128 1 132 143 2-s2.0-78349253777 10.1002/ijc.25330
45. Leidner R. S., Ravi L., Leahy P., The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012 51 5 473 479
46. Revilla-Nuin B., Parrilla P., Lozano J., Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Annals of Surgery 2012
47. Luzna P., Gregar J., Uberall I., Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagnostic Pathology 2011 6, article 114
48. Kadri S. R., Lao-Sirieix P., O'Donovan M., Debiram I., Das M., Blazeby J. M., Emery J., Boussioutas A., Morris H., Walter F. M., Pharoah P., Hardwick R. H., Fitzgerald R. C., Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. British Medical Journal 2010 341 c4372 2-s2.0-77957035085 10.1136/bmj.c4372
49. Lao-Sirieix P., Boussioutas A., Kadri S. R., O'Donovan M., Debiram I., Das M., Harihar L., Fitzgerald R. C., Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009 58 11 1451 1459 2-s2.0-70350223628 10.1136/gut.2009.180281
50. Rygiel A. M., Milano F., Ten Kate F. J., De Groot J. G., Peppelenbosch M. P., Bergman J. J. G. H. M., Krishnadath K. K., Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. Genes Chromosomes and Cancer 2008 47 5 396 404 2-s2.0-41349087496 10.1002/gcc.20543 (Pubitemid 351451794)
51. Barr Fritcher E. G., Brankley S. M., Kipp B. R., Voss J. S., Campion M. B., Morrison L. E., Legator M. S., Lutzke L. S., Wang K. K., Sebo T. J., Halling K. C., A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Human Pathology 2008 39 8 1128 1135 2-s2.0-47549114817 10.1016/j.humpath.2008.02.003
52. Dahlberg P. S., Jacobson B. A., Dahal G., Fink J. M., Kratzke R. A., Maddaus M. A., Ferrin L. J., ERBB2 amplifications in esophageal adenocarcinoma. Annals of Thoracic Surgery 2004 78 5 1790 1800 2-s2.0-19644373932 10.1016/j.athoracsur.2004.05.037 (Pubitemid 39423556)
53. Hammoud Z. T., Dobrolecki L., Kesler K. A., Rahmani E., Rieger K., Malkas L. H., Hickey R. J., Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern. Annals of Thoracic Surgery 2007 84 2 384 392 2-s2.0-34447580916 10.1016/j.athoracsur.2007.03.088 (Pubitemid 47069198)
54. Murray L., Sedo A., Scott M., McManus D., Sloan J. M., Hardie L. J., Forman D., Wild C. P., TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006 55 10 1390 1397 2-s2.0-33749167729 10.1136/gut.2005.083295 (Pubitemid 44476779)
55. Weston A. P., Banerjee S. K., Sharma P., Tran T. M., Richards R., Cherian R., p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. American Journal of Gastroenterology 2001 96 5 1355 1362 2-s2.0-0035007905 10.1016/S0002-9270(01)02414-5 (Pubitemid 32455059)
56. Reid B. J., Levine D. S., Longton G., Blount P. L., Rabinovitch P. S., Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. American Journal of Gastroenterology 2000 95 7 1669 1676 2-s2.0-0033915683 10.1016/S0002- 9270(00)00988-6 (Pubitemid 30485000)
57. Rabinovitch P. S., Longton G., Blount P. L., Levine D. S., Reid B. J., Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. American Journal of Gastroenterology 2001 96 11 3071 3083 2-s2.0-0035180041 10.1016/S0002-9270(01)03823-0 (Pubitemid 33095344)
58. Reid B. J., Prevo L. J., Galipeau P. C., Sanchez C. A., Longton G., Levine D. S., Blount P. L., Rabinovitch P. S., Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. American Journal of Gastroenterology 2001 96 10 2839 2848 2-s2.0-0034793846 10.1016/S0002-9270(01) 02798-8 (Pubitemid 32959522)
59. Galipeau P. C., Li X., Blount P. L., Maley C. C., Sanchez C. A., Odze R. D., Ayub K., Rabinovitch P. S., Vaughan T. L., Reid B. J., NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Medicine 2007 4 2, article e67 2-s2.0-33847617509 10.1371/journal.pmed. 0040067 (Pubitemid 46354447)
60. Merlo L. M. F., Shah N. A., Li X., Blount P. L., Vaughan T. L., Reid B. J., Maley C. C., A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prevention Research 2010 3 11 1388 1397 2-s2.0-78649248733 10.1158/1940-6207.CAPR-10-0108
61. Cronin J., McAdam E., Danikas A., Tselepis C., Griffiths P., Baxter J., Thomas L., Manson J., Jenkins G., Epidermal Growth Factor Receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's Esophagus (BE). American Journal of Gastroenterology 2011 106 1 46 56 2-s2.0-78650978994 10.1038/ajg.2010.433
62. Sirieix P. S., O'Donovan M., Brown J., Save V., Coleman N., Fitzgerald R. C., Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clinical Cancer Research 2003 9 7 2560 2566 2-s2.0-0037479835 (Pubitemid 36842097)
63. Lao-Sirieix P., Lovat L., Fitzgerald R. C., Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clinical Cancer Research 2007 13 2 659 665 2-s2.0-33846869303 10.1158/1078-0432.CCR-06-1385 (Pubitemid 46225374)
64. Bani-Hani K., Martin I. G., Hardie L. J., Mapstone N., Briggs J. A., Forman D., Wild C. P., Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. Journal of the National Cancer Institute 2000 92 16 1316 1321 2-s2.0-0034674912 (Pubitemid 30660591)
65. Wang J. S., Guo M., Montgomery E. A., Thompson R. E., Cosby H., Hicks L., Wang S., Herman J. G., Canto M. I., DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in barrett's esophagus. American Journal of Gastroenterology 2009 104 9 2153 2160 2-s2.0-69949111978 10.1038/ajg.2009.300
66. Jin Z., Cheng Y., Gu W., Zheng Y., Sato F., Mori Y., Olaru A. V., Paun B. C., Yang J., Kan T., Ito T., Hamilton J. P., Selaru F. M., Agarwal R., David S., Abraham J. M., Wolfsen H. C., Wallace M. B., Shaheen N. J., Washington K., Wang J., Canto M. I., Bhattacharyya A., Nelson M. A., Wagner P. D., Romero Y., Wang K. K., Feng Z., Sampliner R. E., Meltzer S. J., A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Research 2009 69 10 4112 4115 2-s2.0-66249114998 10.1158/0008-5472.CAN-09-0028
67. Dahlberg P. S., Ferrin L. F., Grindle S. M., Nelson C. M., Hoang C. D., Jacobson B., Gene expression profiles in esophageal adenocarcinoma. Annals of Thoracic Surgery 2004 77 3 1008 1015 2-s2.0-1442349114 10.1016/j.athoracsur. 2003.09.051 (Pubitemid 38271078)
68. Breton J., Gage M. C., Hay A. W., Keen J. N., Wild C. P., Donnellan C., Findlay J. B. C., Hardie L. J., Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in barrett's esophagus and esophageal adenocarcinoma. Journal of Proteome Research 2008 7 5 1953 1962 2-s2.0-52049108091 10.1021/pr7007835
69. Fang M., Lew E., Klein M., Sebo T., Su Y., Goyal R., DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. American Journal of Gastroenterology 2004 99 10 1887 1894 2-s2.0-7044286361 10.1111/j.1572-0241. 2004.30886.x (Pubitemid 39421229)
70. Yu C., Zhang X., Huang Q., Klein M., Goyal R. K., High-fidelity DNA histograms in neoplastic progression in Barrett's esophagus. Laboratory Investigation 2007 87 5 466 472 2-s2.0-34247365618 10.1038/labinvest.3700531 (Pubitemid 46633121)
71. Vogt N., Schönegg R., Gschossmann J. M., Borovicka J., Benefit of baseline cytometry for surveillance of patients with Barrett's esophagus. Surgical Endoscopy and Other Interventional Techniques 2010 24 5 1144 1150 2-s2.0-77955657074 10.1007/s00464-009-0741-7
72. Li X., Galipeau P. C., Sanchez C. A., Blount P. L., Maley C. C., Arnaudo J., Peiffer D. A., Pokholok D., Gunderson K. L., Reid B. J., Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prevention Research 2008 1 6 413 423 2-s2.0-61749087820 10.1158/1940-6207.CAPR-08-0121
73. Prasad G. A., Wang K. K., Halling K. C., Buttar N. S., Wongkeesong L. M., Zinsmeister A. R., Brankley S. M., Fritcher E. G. B., Westra W. M., Krishnadath K. K., Lutzke L. S., Borkenhagen L. S., Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008 135 2 370 379 2-s2.0-48549106609 10.1053/j.gastro.2008.04.036
74. Dunn J. M., MacKenzie G. D., Oukrif D., Mosse C. A., Banks M. R., Thorpe S., Sasieni P., Bown S. G., Novelli M. R., Rabinovitch P. S., Lovat L. B., Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy. British Journal of Cancer 2010 102 11 1608 1617 2-s2.0-77952889140 10.1038/sj.bjc.6605688
75. Langer R., Ott K., Specht K., Becker K., Lordick F., Burian M., Herrmann K., Schrattenholz A., Cahill M. A., Schwaiger M., Hofler H., Wester H. J., Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clinical Cancer Research 2008 14 24 8279 8287 2-s2.0-58149331113 10.1158/1078-0432.CCR-08-0679
76. Schauer M., Janssen K. P., Rimkus C., Raggi M., Feith M., Friess H., Theisen J., Microarray-based response prediction in esophageal adenocarcinoma. Clinical Cancer Research 2010 16 1 330 337 2-s2.0-74949101064 10.1158/1078-0432.CCR-09-1673
77. Wu X., Gu J., Wu T. T., Swisher S. G., Liao Z., Correa A. M., Liu J., Etzel C. J., Amos C. I., Huang M., Chiang S. S., Milas L., Hittelman W. N., Ajani J. A., Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. Journal of Clinical Oncology 2006 24 23 3789 3798 2-s2.0-33747344251 10.1200/JCO.2005.03.6640 (Pubitemid 46628477)
78. Heeren P. A. M., Kloppenberg F. W. H., Hollema H., Mulder N. H., Nap R. E., Plukker J. T. M., Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Research 2004 24 4 2579 2583 2-s2.0-4444320783 (Pubitemid 39166351)
79. Nakashima S., Natsugoe S., Matsumoto M., Kijima F., Takebayashi Y., Okumura H., Shimada M., Nakano S., Kusano C., Baba M., Takao S., Aikou T., Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Research 2000 20 3 B 1933 1937 2-s2.0-0033869334 (Pubitemid 30636160)
80. Kim M. K., Cho K. J., Kwon G. Y., Park S. I., Kim Y. H., Kim J. H., Song H. Y., Shin J. H., Jung H. Y., Lee G. H., Choi K. D., Kim S. B., ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. European Journal of Cancer 2008 44 1 54 60 2-s2.0-37149046306 10.1016/j.ejca.2007.09.006 (Pubitemid 350256935)
81. Peters C. J., Rees J. R. E., Hardwick R. H., Hardwick J. S., Vowler S. L., Ong C. J., Zhang C., Save V., O'Donovan M., Rassl D., Alderson D., Caldas C., Fitzgerald R. C., A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010 139 6 1995.e15 2004.e15 2-s2.0-78649704141 10.1053/j.gastro.2010.05.080
82. Prasad G. A., Wang K. K., Halling K. C., Buttar N. S., Wongkeesong L. M., Zinsmeister A. R., Brankley S. M., Westra W. M., Lutzke L. S., Borkenhagen L. S., Dunagan K., Correlation of histology with biomarker status after photodynamic therapy in barrett esophagus. Cancer 2008 113 3 470 476 2-s2.0-49049113051 10.1002/cncr.23573
83. Lagarde S. M., Ver Loren Van Themaat P. E., Moerland P. D., Gilhuijs-Pederson L. A., Ten Kate F. J. W., Reitsma P. H., Van Kampen A. H. C., Zwinderman A. H., Baas F., Van Lanschot J. J. B., Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Annals of Surgical Oncology 2008 15 12 3459 3470 2-s2.0-58149277496 10.1245/s10434-008- 0165-y
84. Mathé E. A., Nguyen G. H., Bowman E. D., MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: Associations with survival. Clinical Cancer Research 2009 15 19 6192 6200
85. Pasello G., Agata S., Bonaldi L., Corradin A., Montagna M., Zamarchi R., Parenti A., Cagol M., Zaninotto G., Ruol A., Ancona E., Amadori A., Saggioro D., DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. Modern Pathology 2009 22 1 58 65 2-s2.0-58149166878 10.1038/modpathol.2008.150
86. Izzo J. G., Wu T. T., Wu X., Ensor J., Luthra R., Pan J., Correa A., Swisher S. G., Chao C. K. S., Hittelman W. N., Ajani J. A., Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. Journal of Clinical Oncology 2007 25 6 698 707 2-s2.0-33947611435 10.1200/JCO.2006.08.0283 (Pubitemid 350002926)
87. Wang K. L., Wu T. T., In S. C., Wang H., Reseetkova E., Correa A. M., Hofstetter W. L., Swisher S. G., Ajani J. A., Rashid A., Albarracin C. T., Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007 109 4 658 667 2-s2.0-33846928248 10.1002/cncr.22445 (Pubitemid 46233226)
88. Langer R., Von Rahden B. H. A., Nahrig J., Von Weyhern C., Reiter R., Feith M., Stein H. J., Siewert J. R., Höfler H., Sarbia M., Prognostic significance of expression patterns of c-erbB-2, p53, p16 INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. Journal of Clinical Pathology 2006 59 6 631 634 2-s2.0-33745110595 10.1136/jcp.2005.034298 (Pubitemid 43886048)
89. Falkenback D., Nilbert M., Öberg S., Johansson J., Prognostic value of cell adhesion in esophageal adenocarcinomas. Diseases of the Esophagus 2008 21 2 97 102 2-s2.0-39049139719 10.1111/j.1442-2050.2007.00749.x (Pubitemid 351247319)
90. Brien T. P., Odze R. D., Sheehan C. E., McKenna B. J., Ross J. S., Her-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Human Pathology 2000 31 1 35 39 2-s2.0-0033963379 (Pubitemid 30054384)
91. Ross J. S., McKenna B. J., The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investigation 2001 19 5 554 568 2-s2.0-0034929997 10.1081/CNV-100103852 (Pubitemid 32619394)
92. Aloia T. A., Harpole D. H. Jr., Reed C. E., Allegra C., Moore M. H., Herndon J. E., D'Amico T. A., Tumor marker expression is predictive of survival in patients with esophageal cancer. Annals of Thoracic Surgery 2001 72 3 859 866 2-s2.0-0034849343 10.1016/S0003-4975(01)02838-7 (Pubitemid 32846247)
93. D'Errico A., Barozzi C., Fiorentino M., Carella R., Di Simone M., Ferruzzi L., Mattioli S., Grigioni W. F., Role and new perspectives of transforming growth factor- α (TGF- α) in adenocarcinoma of the gastro-oesophageal junction. British Journal of Cancer 2000 82 4 865 870 2-s2.0-0033951065 (Pubitemid 30085240)
94. Von Rahden B. H. A., Stein H. J., Feith M., Pühringer F., Theisen J., Siewert J. R., Sarbia M., Overexpression of TGF- β 1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Molecular Carcinogenesis 2006 45 10 786 794 2-s2.0-33749259074 10.1002/mc.20259 (Pubitemid 44484989)
95. Fukuchi M., Miyazaki T., Fukai Y., Nakajima M., Sohda M., Masuda N., Manda R., Tsukada K., Kato H., Kuwano H., Plasma level of transforming growth factor β 1 measured from the azygos vein predicts prognosis in patients with esophageal cancer. Clinical Cancer Research 2004 10 8 2738 2741 2-s2.0-11144357297 10.1158/1078-0432.CCR-1096-03 (Pubitemid 38509149)
96. Kawakami K., Brabender J., Lord R. V., Groshen S., Greenwald B. D., Krasna M. J., Yin J., Fleisher A. S., Abraham J. M., Beer D. G., Sidransky D., Huss H. T., Demeester T. R., Eads C., Laird P. W., Ilson D. H., Kelsen D. P., Harpole D., Moore M. B., Danenberg K. D., Danenberg P. V., Meltzer S. J., Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. Journal of the National Cancer Institute 2000 92 22 1805 1811 2-s2.0-0034669126
97. Raouf A. A., Evoy D. A., Carton E., Mulligan E., Griffin M. M., Reynolds J. V., Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Diseases of the Esophagus 2003 16 1 17 23 2-s2.0-0037953174 10.1046/j.1442-2050.2003.00281.x (Pubitemid 36603489)
98. Bhandari P., Bateman A. C., Mehta R. L., Stacey B. S. F., Johnson P., Cree I. A., Di Nicolantonio F., Patel P., Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer 2006 6, article 134 2-s2.0-33745315686 10.1186/1471-2407-6-134 (Pubitemid 43933648)
99. France M., Drew P. A., Dodd T., Watson D. I., Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Diseases of the Esophagus 2004 17 2 136 140 2-s2.0-4043144288 10.1111/j.1442-2050.2004.00390.x (Pubitemid 39076934)
100. Buskens C. J., Van Rees B. P., Sivula A., Reitsma J. B., Haglund C., Bosma P. J., Offerhaus G. J., Van Lanschot J. J., Ristimäki A., Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002 122 7 1800 1807 2-s2.0-0036083347 (Pubitemid 34651424)
101. Izzo J. G., Malhotra U., Wu T. T., Ensor J., Luthra R., Lee J. H., Swisher S. G., Liao Z., Chao K. S. C., Hittelman W. N., Aggarwal B. B., Ajani J. A., Association of activated transcription factor nuclear factor B with chemoradiation resistance and poor outcome in esophageal carcinoma. Journal of Clinical Oncology 2006 24 5 748 754 2-s2.0-33644853585 10.1200/JCO.2005.03.8810 (Pubitemid 46622041)
102. Gertler R., Doll D., Maak M., Feith M., Rosenberg R., Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer 2008 112 10 2173 2180 2-s2.0-43049132485 10.1002/cncr.23419 (Pubitemid 351628626)
103. Saad R. S., El-Gohary Y., Memari E., Liu Y. L., Silverman J. F., Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Human Pathology 2005 36 9 955 961 2-s2.0-24344497408 10.1016/j.humpath.2005.06.019 (Pubitemid 41253380)
104. Nekarda H., Schlegel P., Schmitt M., Stark M., Mueller J. D., Fink U., Siewert J. R., Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clinical Cancer Research 1998 4 7 1755 1763 2-s2.0-0031776764 (Pubitemid 28304739)
105. Darnton S. J., Hardie L. J., Muc R. S., Wild C. P., Casson A. G., Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. International Journal of Cancer 2005 115 3 351 358 2-s2.0-18644384743 10.1002/ijc.20830 (Pubitemid 40663737)
106. Brock M. V., Gou M., Akiyama Y., Muller A., Wu T. T., Montgomery E., Deasel M., Germonpré P., Rubinson L., Heitmiller R. F., Yang S. C., Forastiere A. A., Baylin S. B., Herman J. G., Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clinical Cancer Research 2003 9 8 2912 2919 2-s2.0-12444268993 (Pubitemid 36993249)
107. Baumann S., Keller G., Pühringer F., Napieralski R., Feith M., Langer R., Höfler H., Stein H. J., Sarbia M., The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promoter hypermethylation in esophageal adenocarcinoma. International Journal of Cancer 2006 119 2 264 268 2-s2.0-33745221008 10.1002/ijc.21848
108. Smith C. M., Michael M. Z., Watson D. I., Impact of gastroesophageal reflux on microRNA expression, location and function. BMC Gastroenterology 2013 13 1, article 4
109. Gregory P. A., Bert A. G., Paterson E. L., Barry S. C., Tsykin A., Farshid G., Vadas M. A., Khew-Goodall Y., Goodall G. J., The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology 2008 10 5 593 601 2-s2.0-43049103824 10.1038/ncb1722 (Pubitemid 351627379)
110. Russo A., Bronte G., Cabibi D., The molecular changes driving the carcinogenesis in Barrett's esophagus: which came first, the chicken or the egg? Critical Reviews in Oncology/Hematology 2013
111. Ong C. A. J., Lao-Sirieix P., Fitzgerald R. C., Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World Journal of Gastroenterology 2010 16 45 5669 5681 2-s2.0-78649887198 10.3748/wjg.v16.i45.5669
112. Fang D., Das K. M., Cao W., Barrett's esophagus: progression to adenocarcinoma and markers. Annals of the New York Academy of Sciences 2011 1232 210 229
113. Huang Q., Hardie L. J., Biomarkers in Barrett's oesophagus. Biochemical Society Transactions 2010 38 2 343 347 2-s2.0-77953273951 10.1042/BST0380343
114. Jankowski J. A., Odze R. D., Biomarkers in gastroenterology: between hope and hype comes histopathology. American Journal of Gastroenterology 2009 104 5 1093 1096 2-s2.0-66949128313 10.1038/ajg.2008.172
115. Varghese S., Lao-Sirieix P., Fitzgerald R. C., Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology 2012 142 3 435 441
116. Riddell R. H., Odze R. D., Definition of barrett's esophagus: time for a rethinkis intestinal metaplasia dead. American Journal of Gastroenterology 2009 104 10 2588 2594 2-s2.0-70350491200 10.1038/ajg.2009.390
117. Sobin L. H., Gospodarowicz M. K., Wittekind C., TNM Classification of Malignant Tumours 2010 7 7th
118. Moyes L. H., Going J. J., Still waiting for predictive biomarkers in Barrett's oesophagus. Journal of Clinical Pathology 2011 64 9 742 750
119. Coussens L. M., Werb Z., Inflammation and cancer. Nature 2002 420 6917 860 867 2-s2.0-0037180757 10.1038/nature01322 (Pubitemid 36019639)
120. Poehlmann A., Kuester D., Malfertheiner P., Inflammation and Barrett's carcinogenesis. Pathology, Research and Practice 2012 208 5 269 280
121. Kiesslich T., Pichler M., Neureiter D., Epigenetic control of epithelial-mesenchymal-transition in human cancer (Review). Molecular and Clinical Oncology 2013 1 3 11
122. Jethwa P., Naqvi M., Hardy R. G., Hotchin N. A., Roberts S., Spychal R., Tselepis C., Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World Journal of Gastroenterology 2008 14 7 1044 1052 2-s2.0-40149110961 10.3748/wjg.14.1044 (Pubitemid 351325004)
123. Bird-Lieberman E. L., Dunn J. M., Coleman H. G., Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012 143 4 927 935
124. El Omar E. M., Jankowski J., Genetics of Barrett's: the bigger, the better. American Journal of Gastroenterology 2012 107 9 1342 1345
125. Kaz A. M., Wong C. J., Luo Y., DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics 2011 6 12 1403 1412
126. Ko M. A., Zehong G., Virtanen C., MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Annals of Thoracic Surgery 2012 94 4 1094 1102